Search - tctmd.com

Displaying 61 - 80 of 133

Sort: Relevancy | Date

Presentation TVT 2017

A Model of TAVR (vs SAVR) Case Selection, Based Solely on Clinical and Anatomic Factors

Presenter: David J. Cohen, Jeffrey J. Popma, Martin B. Leon

June 16, 2017

Presentation TVT 2017

After PARTNER 2A/S3i and SURTAVI, What Is the Role of Surgery in Intermediate-Risk AS Patients?

Presenter: David J. Cohen, Jeffrey J. Popma, Vinod H. Thourani

June 16, 2017

Presentation TVT 2017

SURTAVI Vignette III: Subset Analysis of Strokes

Presenter: David J. Cohen, Jeffrey J. Popma, A. Pieter Kappetein

June 16, 2017

Presentation TVT 2017

SURTAVI Vignette II: Subset Analysis of Patients With STS < 3% (Lower-Risk Patients)

Presenter: David J. Cohen, Jeffrey J. Popma

June 16, 2017

Presentation TVT 2017

SURTAVI Vignette I: Applying Bayesian Methodology to Interventional Clinical Trials

Presenter: David J. Cohen, Jeffrey J. Popma

June 16, 2017

Presentation TVT 2017

Spotlight Lecture: The SURTAVI LBCT: CoreValve vs Surgery in Intermediate-Risk Aortic Stenosis Patients

Presenter: David J. Cohen, Jeffrey J. Popma, Michael J. Reardon

June 16, 2017

Presentation TVT 2017

Prevalence of Amyloid in Patients Undergoing TAVR: Low-Flow Phenotype and Echocardiographic Predictors

Presenter: David J. Cohen, Mark J. Russo, Adam Castano

June 16, 2017

Presentation TVT 2017

TAVR to Treat Aortic Regurgitation in LVAD Patients Rationale and Case Examples

Presenter: David J. Cohen, Mark J. Russo, Nir Uriel

June 16, 2017

Presentation TVT 2017

Emergent TAVR for AS Patients With Intractable Heart Failure: Feasibility and Early Clinical Results

Presenter: David J. Cohen, Mark J. Russo, Ran Kornowski

June 16, 2017

Presentation TVT 2017

Who Shouldnt Undergo TAVR? Can We Identify Non-responders?

Presenter: David J. Cohen, Mark J. Russo, Suzanne V. Arnold

June 16, 2017

Presentation TVT 2017

Ineffective Endocarditis After TAVR: Cause for Concern?

Presenter: David J. Cohen, Mark J. Russo, Bernard Prendergast

June 16, 2017

Presentation TVT 2017

Gender Differences in TAVR Outcomes Recent Analyses in Intermediate-Risk Patients

Presenter: David J. Cohen, Mark J. Russo, Molly Szerlip

June 16, 2017

Presentation TVT 2017

Optimizing Outcomes of Valve-in-Valve TAVR: The Role of Bioprosthetic Valve Fracture

Presenter: Ran Kornowski, Mark J. Russo, David J. Cohen

June 15, 2017

Presentation Fellows 2017

Essentials of Clinical Trial Design: Statistics 101 for the Budding Interventionalist

Presenter: Sahil A. Parikh, David J. Cohen

April 08, 2017

Presentation Fellows 2017

How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy

Presenter: Manish A. Parikh, David J. Cohen

April 07, 2017

Presentation Fellows 2017

Antithrombin Therapy for the Interventionalist

Presenter: Manish A. Parikh, David J. Cohen

April 07, 2017

Presentation TCT 2016

Opening Salvo: I Don't Believe That Door-to-Balloon Time Is a Critical Metric for Primary PCI In 2016!

Presenter: David J. Cohen, Ajay J. Kirtane, Alan C. Yeung, Hitinder S. Gurm

November 01, 2016

Presentation TCT 2016

Opening Salvo: I Don't Believe That DAPT Should Be Continued Beyond 12 Months in Most Patients Undergoing PCI!

Presenter: David J. Cohen, Ajay J. Kirtane, Alan C. Yeung, Gennaro Giustino

November 01, 2016

Presentation TCT 2016

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, David J. Cohen

November 01, 2016

Presentation TCT 2016

Strategy Trials: ISCHEMIA/EXCEL/FREEDOM: Strengths and Weaknesses

Presenter: Stuart J. Pocock, Jan G. P. Tijssen, David J. Cohen

November 01, 2016

Advertisement

A Model of TAVR (vs SAVR) Case Selection, Based Solely on Clinical and Anatomic Factors

After PARTNER 2A/S3i and SURTAVI, What Is the Role of Surgery in Intermediate-Risk AS Patients?

SURTAVI Vignette III: Subset Analysis of Strokes

SURTAVI Vignette II: Subset Analysis of Patients With STS < 3% (Lower-Risk Patients)

SURTAVI Vignette I: Applying Bayesian Methodology to Interventional Clinical Trials

Spotlight Lecture: The SURTAVI LBCT: CoreValve vs Surgery in Intermediate-Risk Aortic Stenosis Patients

Prevalence of Amyloid in Patients Undergoing TAVR: Low-Flow Phenotype and Echocardiographic Predictors

TAVR to Treat Aortic Regurgitation in LVAD Patients Rationale and Case Examples

Emergent TAVR for AS Patients With Intractable Heart Failure: Feasibility and Early Clinical Results

Who Shouldnt Undergo TAVR? Can We Identify Non-responders?

Ineffective Endocarditis After TAVR: Cause for Concern?

Gender Differences in TAVR Outcomes Recent Analyses in Intermediate-Risk Patients

Optimizing Outcomes of Valve-in-Valve TAVR: The Role of Bioprosthetic Valve Fracture

Essentials of Clinical Trial Design: Statistics 101 for the Budding Interventionalist

How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy

Antithrombin Therapy for the Interventionalist

Opening Salvo: I Don't Believe That Door-to-Balloon Time Is a Critical Metric for Primary PCI In 2016!

Opening Salvo: I Don't Believe That DAPT Should Be Continued Beyond 12 Months in Most Patients Undergoing PCI!

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Strategy Trials: ISCHEMIA/EXCEL/FREEDOM: Strengths and Weaknesses

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content